SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London's Andrew Scott they're looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It's part of their collaboration with Winclove Probiotics which is well ahead of schedule. Ashman adds that their work with partner Croda to develop an active skincare ingredient is also making good progress.
viewSkinBioTherapeutics PLC
SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement
Quick facts: SkinBioTherapeutics PLC
Price: 26.5 GBX
AIM:SBTX
Market: AIM
Market Cap: £33.94 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
SkinBioTherapeutics’ has big plans for SkinBiotix
Most read
Mining
Are small-cap nickel stocks a 'buy' as Tesla CEO sets challenge to miners?
13 hours, 34 minutes ago
Mining
Horizonte Minerals hails "significant milestone" as five banks tasked with...
2 days, 18 hours ago
